|
DGAP-Ad-hoc: QIAGEN N.V. / Key word(s): Results Forecast Ad hoc Announcement according to Art. 17 Market Abuse Regulation QIAGEN increases full-year 2022 outlook Venlo, The Netherlands, April 26, 2022 - QIAGEN N.V. (NYSE: QGEN; Frankfurt Prime Standard: QIA) announces that it has increased the outlook for full-year 2022 in terms of net sales and adjusted diluted earnings per share (EPS). Net sales are now expected to reach at least $2.12 billion CER (prior outlook for at least $2.07 billion CER) compared to the full-year 2021 results of $2.25 billion. Adjusted diluted EPS are now expected to be at least $2.14 CER per share (prior outlook for at least $2.05 CER per share) compared to the full-year 2021 results of $2.65 per share. The updated outlook takes into consideration a review that included the strong start to the year in the first quarter of 2022. It also reflects a reaffirmation of the previous goal for double-digit CER sales growth from the non-COVID product groups, but for a significant year-on-year decline in COVID-19 product group sales based on expectations for volatile pandemic trends in 2022. Also taken into consideration was an updated assessment of current inflation and macro-economic trends. This includes the adverse impact of anticipated lost sales in 2022 from Russia, Ukraine and Belarus as a result of the war in Ukraine. These countries represented approximately 1% of total QIAGEN sales in 2021. QIAGEN continues to make ongoing investments into its portfolio, in particular the five pillars of growth, for new products, test menu and applications. This outlook does not take into consideration any future acquisitions. QIAGEN N.V. Hulsterweg 82 5912 PL Venlo The Netherlands ISIN: NL0012169213 Frankfurt Stock Exchange, Regulated Market (Prime Standard) Contacts QIAGEN N.V.: Corporate Communications John Gilardi, Tel: +49 2103 29 11711; john.gilardi@qiagen.com
26-Apr-2022 CET/CEST The DGAP Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases. |
| Language: | English |
| Company: | QIAGEN N.V. |
| Hulsterweg 82 | |
| 5912 PL Venlo | |
| Netherlands | |
| Phone: | +31 7735566 - 00 |
| Fax: | +31 77 35566-58 |
| E-mail: | qiagen@qiagen.com |
| Internet: | www.qiagen.com |
| ISIN: | NL0012169213 |
| WKN: | A2DKCH |
| Indices: | DAX, TecDAX |
| Listed: | Regulated Market in Berlin, Frankfurt (Prime Standard); Regulated Unofficial Market in Dusseldorf, Hamburg, Hanover, Munich, Stuttgart, Tradegate Exchange; London, Chicago, NYSE, SIX |
| EQS News ID: | 1336059 |
| End of Announcement | DGAP News Service |
|
|
1336059 26-Apr-2022 CET/CEST
P R O D U C T S U G G E S T I O N S
The information presented here has been provided by our content partner EQS-Group. The originator of the news is the respective issuer, the company relating to the news, a publication service provider (press or information agency) which uses the distribution service of EQS to transmit company news to shareholders, investors, investors or interested parties. The original publications and other company-relevant information can be found at eqs-news.com.
The information you can access does not constitute investment advice. The presentation of our cooperation partners, where the implementation of investment decisions would be possible depending on the individual risk profile, is solely at the discretion of the person using the service. We only present companies of which we are convinced that the range of services and customer service will satisfy discerning investors.
If you are considering leverage products, familiarise yourself with the typical characteristics of the financial instruments beforehand. Take the time to determine the risk content of the planned investment before making an investment decision. Bear in mind that a total loss cannot be ruled out with leverage products.
For newcomers to the subject, we offer various options in both the training and the tools section, through which you can train theoretical knowledge and practical experience and thus improve your skills. The offer ranges from participation in webinars to personal mentoring. The range is continuously being expanded.
1 Lab features are usually functionalities that emerge from the think tank of the investor community. In the early stages, these are experimental functionalities whose development process is largely determined by use and the resulting feedback from the community. When integrating external services or functionalities, the functionality can only be guaranteed to the extent that the individual process elements, such as interfaces, interact with each other.
